Identity of Investigational Products in Clinical Study Report
ICH E3 section 9.4.2 calls for identification of the investigational/test product and relevant comparator or placebo information in the report. Report product identity at the level needed by ICH E3; do not turn this subsection into a general manufacturing dossier or duplicate unrelated product-quality documentation.
ReviewedEvidence1 sourceSectionWriting & Style
Quick answer
Give the relevant product identity details needed to understand what was administered, such as formulation, strength, and batch information where applicable, together with comparator or placebo source information when relevant.
Key details
Core IssueICH E3 section 9.4.2 calls for identification of the investigational/test product and relevant comparator or placebo information in the report.
Registerscholarly, professional, or research/report writing
Important caveats
Scope Boundary
Report product identity at the level needed by ICH E3; do not turn this subsection into a general manufacturing dossier or duplicate unrelated product-quality documentation.
Further guidance
Content
Give the relevant product identity details needed to understand what was administered, such as formulation, strength, and batch information where applicable, together with comparator or placebo source information when relevant.
Purpose
Give the relevant product identity details needed to understand what was administered, such as formulation, strength, and batch information where applicable, together with comparator or placebo source information when relevant.
Sources and evidence
Sources are shown with the role they play in this guide. Historical or style-sensitive claims are kept within the evidence boundary described above.
ICH E3 section 12.3.3 calls for analysis and discussion across deaths, other serious adverse events, and other significant adverse events after the relevant case listings and narratives. This is an interpretive synthesis, not a duplicate death/serious-event listing or a replacement for individual patient narratives.
ICH E3 section 12.2.3 calls for analysis of adverse events beyond their tabular display, focusing on patterns important to safety interpretation. Do not treat the analysis as a substitute for the event display or patient-level listing, and do not imply causality beyond what the study evidence supports.
ICH E3 section 9.5.2 calls for discussion of the appropriateness, reliability, or relevance of measurements used to assess efficacy and safety when explanation is needed. This subsection justifies or qualifies measurement choices; it does not replace the section that defines the variables, methods, and timing of assessments.
ICH E3 section 12.2.1 calls for a brief summary of adverse events within the safety evaluation before more detailed displays and analyses. Keep this section a high-level summary; it is not a substitute for detailed adverse-event displays, patient-level listings, serious-event treatment, or narratives.
ICH E3 section 9.8 calls for changes made after the study began to the conduct of the study or planned analyses to be described, including timing, reasons, decision process, responsibility, available data, and interpretive implications as applicable. This section is broader than a statistical-methods subsection: it covers material study-conduct changes as well as planned-analysis changes, while detailed statistical methods remain in their dedicated section.
ICH E3 section 9.2 calls for discussion of the chosen control and study design, including design problems or biases that may matter for interpretation. This guide concerns the rationale and limitations of the control/design choice; the Study Design guide owns the descriptive overview of the study configuration itself.
ICH E3 section 12.2.2 provides for structured display of adverse events as part of the clinical study report safety evaluation. A summary display is distinct from patient-level adverse-event listings and from narratives of selected serious or otherwise significant cases.
ICH E3 section 11.4.2.6 calls for efficacy analyses in relevant patient subsets to be presented or discussed when subgroup evidence is important to interpretation. Keep a defined efficacy subset distinct from the primary analysis population and from exploratory subgroup claims that require their own interpretation.
